Continuous Levalbuterol for Treatment of Status Asthmaticus in Children
Asthma
About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, Levalbuterol, Albuterol, Children
Eligibility Criteria
Inclusion Criteria: Age 6-18 years of age Diagnosis of asthma with two previous visits to emergency department (ED) or primary care provider for asthma care Clinical decision by ED attending physician to begin continuous albuterol after standardized initial ED treatment. Exclusion Criteria: Clinical decision to begin continuous intravenous beta-agonist infusion (e.g. terbutaline) Clinical decision to admit to the Pediatric Intensive Care Unit Drug allergy or other contraindication to RAC or LEV Other concurrent disease such as sickle cell disease, cystic fibrosis, or cardiac disease Pregnancy Prior enrollment in the study
Sites / Locations
- The Children's Hospital of Philadelphia
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
1
2
Nebulized levalbuterol 10mg/hr given continuously
Racemic albuterol 20mg/hr given continuously